Immunology Investor Event
sanofi
Potential to lead in COPD with two biologics to cover
>80% of GOLD D COPD patients
Patient population G7¹ 2035e
Non-Type 2
Type 2
Former
smokers
(70%)
itepekimab²
~1,139K patients
Current
smokers
(30%)
DupixentⓇ3
and
itepekimab²
~640K patients
DupixentⓇ3
only
~270K patients
Up to ~30-40% of patients
with COPD have evidence of
Type 2 inflammation
Both medicines have
potential as 1st COPD
biologic reaching 80% of
highest unmet need patients
Pivotal data expected 2023
and 2024
1. G7 countries: U.S., France, Germany, Italy, Japan, UK, Canada
2. Itepekimab is under investigation and not yet approved by any regulatory agency. Itepekimab is being developed in collaboration with Regeneron.
3. Dupixent is not yet approved for COPD and is being studied in patients with uncontrolled COPD treated with current SoC triple therapy among GOLD D. Patient populations exclude never smokers.
4. Halpin DMG, et al. EClin Med. 2019;14:32-41; Ajithkumar CS, et al. Ind ] Basic Appl Med Res. 2018;7:223-228; Oshagbemi OA, et al. Am J Respir Crit Care Med. 2017;195:1402-1404
13 Immunology Investor EventView entire presentation